マーケットレポート詳細

感染症治療の世界市場：治療薬・ワクチン・診断、2026年予測

Global Markets for Infectious Disease Treatments

出版元：BCC Research 　 出版元について
発行年：2021年12月
定価 Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文245ページになります。
商品コード：BCC350

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

感染症治療の世界市場規模は2021年で724億ドル、2026年に1,063億ドル、市場の平均年成長率は8.0%と予測されています。
治療薬市場については、C型肝炎およびHIV/AIDSが大きい市場になっています。アフリカにおけるマラリア、東南アジアにおける結核などへの治療薬も今後数年間高い成長が見込まれます。治療薬の耐性菌への対策として、より新しい作用機序(MoA)を持つ薬剤への移行およびWHOや各国当局による診断/治療アクセス向上への取り組みが市場を牽引するものと思われます。
ワクチンについては、インフルエンザワクチンの市場規模が最も大きく、今後数年間は4価ワクチンへの移行および高齢者への予防接種が促進要因となると考えられます。

当レポートでは、感染症治療の概要、疾病の概要および市場ダイナミクス、COVID-19の影響、市場/予測、抗生物質耐性、研究開発、次世代予測ツール、特許分析、競合状況、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆概要

・世界における死因の上位
・感染症
・細菌感染症
・ウイルス感染症
・原生動物感染症
・出現/拡散の要因
・ワクチン
・抗生物質

◆疾病の概要および市場ダイナミクス

・B型肝炎とC型肝炎
・HSV(単純ヘルペスウイルス)
・HIV / AIDS
・インフルエンザA/インフルエンザB
・ロタウイルス
・RSウイルス
・マラリア
・結核
・MERS-CoV(中東呼吸器症候群コロナウイルス）
・ラッサ熱
・エボラ熱
・マールブルグ
・ジカウイルス
・黄熱病
・デング熱
※疾病別に地域別の市場予測データ掲載-2026年

◆COVID-19の影響

・歴史
・COVID-19の症状
・COVID-19の進行
・潜伏期間
・疫学
・感染症市場におけるCOVID-19の影響

◆市場/予測

感染症治療の世界市場、治療セグメント別
・治療薬
・ワクチン
・診断

感染症治療の世界市場、感染症別
・B型肝炎およびC型肝炎
・HSV(単純ヘルペスウイルス)
・HIV/ AIDS
・インフルエンザ-AおよびB
・ロタウイルス
・呼吸器合胞体ウイルス
・マラリア
・結核
・MERS-CoV
・ウイルス性出血熱
※治療セグメント別に感染症別および主要地域別でクロス集計した市場予測データ掲載-2026年。詳細は目次List of Tables参照。

◆抗生物質耐性

・概要
・メカニズム
・原因

◆研究開発

・B型肝炎とC型肝炎
・HSV(単純ヘルペスウイルス)
・HIV / AIDS
・インフルエンザA/インフルエンザB
・ロタウイルス
・RSウイルス
・マラリア
・結核
・MERS
・出血熱

◆次世代予測ツール

・予測ツールの必要性
・ツール
・モバイルアプリ
・現在の制約
市場ダイナミクス

◆特許分析-各種疾病別

◆競合状況

・合併/買収/コラボレーション
・市場シェア

◆主要企業プロフィール

ABBOTT
ABBVIE INC.
ASTRAZENECA PHARMACEUTICALS
BRISTOL-MYERS SQUIBB CO.
DIASORIN S.P.A.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
JOHNSON & JOHNSON
MERCK & CO, INC.
NOVARTIS AG                              
ORASURE TECHNOLOGIES INC.
ROCHE
SANOFI S.A.
SEQIRUS, A CSL CO.
SIEMENS HEALTHINEERS
(全245頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
What's New in This Update?
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

Top Global Causes of Death
Infectious Diseases

Bacterial Infectious Diseases
Viral Infectious Diseases
Protozoan Infectious Diseases
Factors Responsible for Emergence and Spread
Vaccines
Antibiotics

Chapter 4 Disease Overview

Hepatitis B and Hepatitis C

Herpes Simplex Virus

HIV/AIDS

Influenza A and Influenza B

Rotavirus

Respiratory Syncytial Virus

Malaria

Tuberculosis

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Viral Hemorrhagic Fevers-Lassa Fever

Viral Hemorrhagic Fevers-Ebola Fever

Viral Hemorrhagic Fevers-Marburg

Viral Hemorrhagic Fevers-Zika Virus

Viral Hemorrhagic Fevers-Yellow Fever

Viral Hemorrhagic Fevers-Dengue

Chapter 5 Market Dynamics

Infectious Diseases

Hepatitis B

Hepatitis C

Herpes

HIV/AIDS

Influenza A and B

Rotavirus

Respiratory Syncytial Virus

Malaria

Tuberculosis

MERS-CoV

Viral Hemorrhagic Fevers-Lassa

Viral Hemorrhagic Fevers-Ebola

Viral Hemorrhagic Fevers-Marburg

Viral Hemorrhagic Fevers-Zika

Viral Hemorrhagic Fevers-Yellow Fever

Viral Hemorrhagic Fevers-Dengue

Chapter 6 Impact of COVID-19

History of Outbreak
Symptoms of COVID-19
Progression of COVID-19
Incubation Period
Epidemiology
Impact of COVID-19 on Infectious Disease Market

Chapter 7 Markets and Forecast

Global Market for Infectious Disease Treatments

Global Infectious Diseases

Chapter 8 Antibiotic Resistance

Overview
Mechanisms of Antibiotic Resistance
Reasons for Antibiotic Resistance

Chapter 9 Research and Development

Overview
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza A and Influenza B
Rotavirus
Respiratory Syncytial Virus
Malaria
Tuberculosis
MERS
Hemorrhagic Fevers

Chapter 10 Next-Generation Predictive Tools

Overview
Why Do We Need Forecast Tools?
Tools in Infectious Disease Modeling
Mobile Apps in Infectious Disease Modeling
Current Limitations in Infectious Disease Modeling

Chapter 11 Patent Analysis

Hepatitis B

Hepatitis C

Herpes Simplex Virus

HIV/AIDS

Influenza

Rotavirus

Respiratory Syncytial Virus

Malaria

Tuberculosis

MERS-CoV

Viral Hemorrhagic Fevers-Lassa

Viral Hemorrhagic Fevers-Ebola

Viral Hemorrhagic Fevers-Marburg

Viral Hemorrhagic Fevers-Zika

Viral Hemorrhagic Fevers-Dengue

Viral Hemorrhagic Fevers-Yellow Fever

Chapter 12 Competitive Landscape

Mergers and Acquisitions and Collaborations
Market Share of Infectious Disease Market

Chapter 13 Company Profiles

ABBOTT
ABBVIE INC.
ASTRAZENECA PHARMACEUTICALS
BRISTOL-MYERS SQUIBB CO.
DIASORIN S.P.A.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
JOHNSON & JOHNSON
MERCK & CO, INC.
NOVARTIS AG
ORASURE TECHNOLOGIES INC.
ROCHE
SANOFI S.A.
SEQIRUS, A CSL CO.
SIEMENS HEALTHINEERS

Chapter 14 Appendix: Abbreviations

"List of Tables

Summary Table : Global Market for Infectious Disease Treatments, by Segment, Through 2026
Table 1 : Leading Causes of Death, Worldwide, by Region, 2019
Table 2 : Leading Causes of Death Due to Infectious Diseases, by Region, 2019
Table 3 : Prevalence and Incidence of Hepatitis B, 2019
Table 4 : Prevalence and Incidence of Hepatitis C, 2019
Table 5 : Global Death Rate Related to Acute Hepatitis B, 1990-2019
Table 6 : Death Rate Related to Acute Hepatitis C, Worldwide, 1990-2019
Table 7 : Prevalence and Incidence of Genital Herpes, Worldwide, 2005-2019
Table 8 : Prevalence of HIV, Adults (15-49 Years Old), by Region, 2020J
Table 9 : New HIV Infections (per 1,000 Uninfected Population), Among all Ages, by Region, 2020
Table 10 : Total Number of New HIV Infections, 2000-2020
Table 11 : Cases of HIV/AIDS Related Deaths, 2000-2020
Table 12 : Years of Life Lost (YLLs), Pandemic Influenza A, H1N1, by Region, 2009
Table 13 : Estimates of Number of RSV Cases per Season for 15 Participating Countries, 2000-2020
Table 14 : Death Rates of RSV-Infected Patients, by WHO Region, 2019
Table 15 : Global Incidence Rate of Malaria Cases, by Region, 2000-2019
Table 16 : Global Confirmed Cases of Malaria in Public Sector, by Region, 2010-2019
Table 17 : Deaths Due to Malaria Worldwide, by Region, 2010-2019
Table 18 : Global Health Expenditures on Malaria Treatment, by Region, 2019
Table 19 : WHO Guidelines for Treatment of Malaria
Table 20 : Treatment Regimen, Drug-Susceptible TB
Table 21 : MERS-CoV Confirmed Cases and Deaths, by Region, January 2016-October 2021
Table 22 : Laboratory Tests for MERS CoV, as Recommended by WHO
Table 23 : Lassa Fever, Confirmed Cases and Deaths, by Region, January 2006-April 2020
Table 24 : Reported Cases and Deaths in Ebola Outbreaks, 2007-February 2021
Table 25 : Reported Cases and Deaths in Marburg Virus, 1998-December 2020
Table 26 : Global Health Burden due to Outbreak of Zika Virus, by Country, 2015-2016
Table 27 : Potential Cases and Deaths Due to Yellow Fever, 1995-2018
Table 28 : Disease Burden–Yellow Fever in Africa, 2019
Table 29 : Deaths Averted due to Mass Vaccinations in Africa, 2019

Table 30 : Global Prevalence and Incidence of Dengue, 2019
Table 31 : COVID-19 Confirmed Cases and Deaths, by Region, as of November 2020
Table 32 : Global Market for Infectious Disease Treatment, by Region, Through 2026
Table 33 : Global Market for Infectious Disease Therapeutics, by Disease Type, Through 2026
Table 34 : Global Market for Infectious Disease Vaccines, by Disease Type, Through 2026
Table 35 : Global Market for Infectious Disease Diagnostics, by Disease Type, Through 2026
Table 36 : Global Market for Hepatitis B Therapeutics, by Region, Through 2026
Table 37 : Global Market for Hepatitis B Vaccines, by Region, Through 2026
Table 38 : Global Market for Hepatitis B Diagnostics, by Region, Through 2026
Table 39 : Global Market for Hepatitis C Therapeutics, by Region, Through 2026
Table 40 : Global Market for Hepatitis C Diagnostics, by Region, Through 2026
Table 41 : Global Market for HSV Therapeutics, by Region, Through 2026
Table 42 : Global Market for HSV Diagnostics, by Region, Through 2026
Table 43 : Global Market for HIV Therapeutics, by Region, Through 2026
Table 44 : Global Market for HIV Diagnostics, by Region, Through 2026
Table 45 : Global Market for Influenza Vaccines, by Region, Through 2026
Table 46 : Global Market for Influenza Diagnostics, by Region, Through 2026
Table 47 : Global Market for Rotavirus Vaccines, by Region, Through 2026
Table 48 : Global Market for Rotavirus Diagnostics, by Region, Through 2026
Table 49 : Global Market for RSV Vaccines, by Region, Through 2026
Table 50 : Global Market for RSV Diagnostics, by Region, Through 2026
Table 51 : Global Market for Malaria Therapeutics, by Region, Through 2026
Table 52 : Global Market for Malaria Vaccines, by Region, Through 2026
Table 53 : Global Market for Malaria Diagnostics (RDTs*), by Region, Through 2026
Table 54 : Global Market for Tuberculosis Therapeutics, by Region, Through 2026
Table 55 : Global Market for Tuberculosis Diagnostics, by Region, Through 2026
Table 56 : Global Market for MERS-CoV Vaccines, by Region, Through 2026
Table 57 : Global Market for Lassa Fever Vaccines, by Region, Through 2026
Table 58 : Global Market for Ebola Fever Vaccines, Through 2026
Table 59 : Global Market for Zika Vaccines, by WHO Region, Through 2026
Table 60 : Global Market for Yellow Fever Vaccines, by WHO Region, Through 2026
Table 61 : Global Market for Dengue Vaccines, by Region, Through 2026
Table 62 : Reported Range of Resistant Population Proportion (%), by Region
Table 63 : WHO Priority List, Pathogens for R&D of New Antibiotics
Table 64 : Global Antibiotics Development Pipeline
Table 65 : Hepatitis B and Hepatitis C Development Pipeline
Table 66 : Herpes Simplex Virus Development Pipeline
Table 67 : HIV/AIDS Development Pipeline
Table 68 : Influenza A and Influenza B Development Pipeline
Table 69 : Rotavirus Development Pipeline
Table 70 : RSV Development Pipeline
Table 71 : Malaria Development Pipeline and Recent Launches
Table 72 : Tuberculosis Development Pipeline
Table 73 : MERS Development Pipeline
Table 74 : Dengue Development Pipeline
Table 75 : Ebola Development Pipeline
Table 76 : Lassa Fever Development Pipeline
Table 77 : Marburg Development Pipeline
Table 78 : Yellow Fever Development Pipeline
Table 79 : Zika Development Pipeline
Table 80 : Hepatitis B Published Patent Applications, 2018-2021
Table 81 : Hepatitis C Published Patent Applications, 2018-2021
Table 82 : Herpes Simplex Virus Published Patent Applications, 2018-2021
Table 83 : HIV/AIDS Published Patent Applications, 2018-2021
Table 84 : Influenza Published Patent Applications, 2018-2021
Table 85 : Rotavirus Published Patent Applications, 2018-2021
Table 86 : Respiratory Syncytial Virus Published Patent Applications, 2018-2021
Table 87 : Malaria Published Patent Applications, 2018-2021
Table 88 : Tuberculosis Published Patent Applications, 2018-2021
Table 89 : MERS Published Patent Applications, 2018-2021
Table 90 : Lassa Fever Published Patent Applications, 2018-2021
Table 91 : Ebola Virus Published Patent Applications, 2018-2021
Table 92 : Marburg Virus Published Patent Applications, 2018-2021
Table 93 : Zika Published Patent Applications, 2018-2021
Table 94 : Dengue Fever Published Patent Applications, 2018-2021
Table 95 : Yellow Fever Published Patent Applications, 2018-2021
Table 96 : Abbott: Product Portfolio, by Business Segment
Table 97 : Abbott: Financials, 2018-2020
Table 98 : AbbVie: Business Segments
Table 99 : AbbVie: Financial Performance, Through 2020
Table 100 : Bristol-Myers Squibb: Financial Performance, 2018-2020
Table 101 : Gilead Sciences: Financial Performance, 2018-2020
Table 102 : GlaxoSmithKline: Product Segments
Table 103 : GlaxoSmithKline: Financial Performance, 2018-2020
Table 104 : Johnson & Johnson: Business Segments
Table 105 : Johnson & Johnson: Financial Performance, 2018-2020
Table 106 : Merck: Business Segments
Table 107 : Merck: Financial Performance, 2018-2020
Table 108 : Roche: Business Segments
Table 109 : Roche: Financial Performance, 2018-2020
Table 110 : Sanofi: Business Segments
Table 111 : Sanofi: Financial Performance, 2018-2020
Table 112 : Abbreviations Used in this Report

"List of Figures

Summary Figure : Global Market for Infectious Disease Treatments, by Segment, 2020-2026
Figure 1 : 20 Leading Causes of Death, Worldwide, 2019
Figure 2 : Leading Causes of Death, Worldwide, by Region, 2019
Figure 3 : Leading Causes of Death Due to Infectious Diseases, by Region, 2019
Figure 4 : Global Vaccination Coverage, by Vaccine, 2020
Figure 5 : Global Death Rate Related to Acute Hepatitis B, 1990-2019
Figure 6 : Years of Life (YLLs) Lost Related to Acute Hepatitis B, Worldwide, 2016-2019
Figure 7 : Death Rate Related to Acute Hepatitis C, Worldwide, 1990-2019
Figure 8 : Years of Life (YLLs) Lost Related to Acute Hepatitis C, Global, 2016-2019
Figure 9 : Disability-affected Life Years (DALYs) Caused by Genital Herpes, Worldwide, 1990-2019
Figure 10 : New HIV Infections, by Region, Worldwide, 2020
Figure 11 : HIV/AIDS Related Deaths, by Region, 2020
Figure 12 : Estimated Number of Deaths Due to 2009 Pandemic Influenza A H1N1, by Region, August 2009-August 2010
Figure 13 : Number of Deaths Due to Rotavirus, Worldwide, 2015-2019
Figure 14 : Highest Number of Infant Deaths Due to Rotavirus, by Country, 2017
Figure 15 : Death Caused by Malaria Worldwide, 2015-2019
Figure 16 : Global Incidence of Tuberculosis, 2015-2020
Figure 17 : Deaths due to Tuberculosis, Worldwide, 1990-2019
Figure 18 : Disability-Adjusted Life Years Caused by Tuberculosis, Worldwide, 1990-2019
Figure 19 : Incidence of Cases and Deaths from Lassa Fever in Nigeria, 2017-2020
Figure 20 : Total Number of Cases due to Ebola Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), March 2014-February 2016
Figure 21 : Deaths Due to Ebola Outbreaks in West Africa (Guinea, Liberia, Sierra Leone), March 2014-February 2016
Figure 22 : Cases and Deaths Due to Major Marburg Outbreaks, 1998–June 2017
Figure 23 : Confirmed Zika Virus Cases in the Americas, 2015-2020
Figure 24 : Countries (Y) with Number of Confirmed Zika Cases (X) in the Americas, 2015-2016
Figure 25 : Global Disability-Adjusted Life Years (DALYs) Due to Yellow Fever, 1995-2019
Figure 26 : Deaths Caused by Yellow Fever, Worldwide, 1995-2019
Figure 27 : Total Number of Dengue Cases Reported in the Americas, 2016-2020
Figure 28 : Incidence Rate of Dengue in the Americas, 2016-2020
Figure 29 : Deaths Caused by Dengue, Worldwide, 2015-2019
Figure 30 : Dengue-Caused Years of Life Lost, Worldwide, 2015-2019
Figure 31 : Global Market for Hepatitis B Vaccines, by Region, 2019–2026
Figure 32 : Global Market for Hepatitis B Vaccines, by Region, 2019–2026
Figure 33 : Global Market for Hepatitis B Diagnostics, by Region, 2019-2026
Figure 34 : Global Market for Hepatitis C Therapeutics, by Region, 2019-2026
Figure 35 : Global Market for Hepatitis C Diagnostics, by Region, 2019–2026
Figure 36 : Global Market for HSV Therapeutics, by Region, 2019-2026
Figure 37 : Global Market for HSV Diagnostics, by Region, 2019-2026
Figure 38 : Global Market for HIV/AIDS Therapeutics, by Region, 2019-2026
Figure 39 : Global Market for HIV Diagnostics, by Region, 2019–2026
Figure 40 : Global Market for Influenza Vaccines, by Region, 2019-2026
Figure 41 : Global Market for Influenza Diagnostics, by Region, 2019-2026
Figure 42 : Global Market for Rotavirus Vaccines, by Region, 2019-2026
Figure 43 : Global Market for Rotavirus Diagnostics, by Region, 2019-2026
Figure 44 : Global Market for RSV Vaccines, by Region, 2019-2026
Figure 45 : Global Market for RSV Diagnostics, by Region, 2019-2026
Figure 46 : Global Market for Malaria Therapeutics, by Region, 2019-2026
Figure 47 : Global Market for Malaria Diagnostics (RDTs*), by Region, 2019-2026
Figure 48 : Global Market for Tuberculosis Therapeutics, by Region, 2019-2026
Figure 49 : Global Market for Tuberculosis Diagnostics, by Region, 2019-2026
Figure 50 : Global Market for MERS-CoV Vaccine, by Region, 2019-2026
Figure 51 : Global Market for Lassa Fever Vaccines, by Region, 2020-2026
Figure 52 : Global Market for Zika Vaccines, by WHO Region, 2019-2026
Figure 53 : Global Market for Yellow Fever Vaccines, by WHO Region, 2019-2026
Figure 54 : Global Market for Dengue Vaccines, by Region, 2019-2026
Figure 55 : Antibiotic Use* by Class, Select Classes, 2000 and 2010
Figure 56 : Shares of Companies in the Global Market for Hepatitis B and C, 2020
Figure 57 : Shares of Companies in the Global Market for HIV/AIDS Therapeutics, 2020
Figure 58 : Shares of Companies in the Global Market for Influenza Vaccines, 2020
Figure 59 : Shares of Companies in the Global Market for Rotavirus Vaccines, 2020
Figure 60 : Abbott: Revenue Share, by Region, 2020
Figure 61 : Abbott: Revenue Share, by Business Segment, 2020
Figure 62 : AbbVie: Net Revenue Share, by Business Segment, 2020
Figure 63 : AbbVie: Net Revenue Share, by Region, 2020
Figure 64 : Bristol Myers Squibb: Sales Share, by Product, 2020
Figure 65 : Bristol-Myers Squibb: Revenue Share, by Region, 2020
Figure 66 : Gilead Sciences: Sales Share, by Product, 2020
Figure 67 : Gilead Sciences: Revenue Share, by Region, 2020
Figure 68 : GlaxoSmithKline: Sales Share, by Product Segment, 2020
Figure 69 : GlaxoSmithKline: Revenue Share, by Region, 2020
Figure 70 : Johnson & Johnson: Sales Share, by Business Segment, 2020
Figure 71 : Johnson & Johnson: Revenue Share, by Region, 2020
Figure 72 : Merck: Revenue Share, by Business Segment, 2020
Figure 73 : Merck: Revenue Share, by Region, 2020
Figure 74 : Roche: Sales Share, by Product Segment, 2020
Figure 75 : Roche: Revenue Share, by Region, 2020
Figure 76 : Sanofi: Sales Share, by Business Segment, 2020
Figure 77 : Sanofi: Sales Share, by Region, 2020


△ 一番上に戻る